Yalos® is comprised of two novel microbes that together improve early vigor, biomass, root and shoot development, and nutrient availability. It aims to improve emergence and establishment and increase farm productivity through advanced biological technologies. Currently, Yalos® is sold in North America as a seed-treatment for spring and winter wheat, durum and barley, distributed in Canada by Winfield United and in the US directly by Lavie Bio. As of spring 2025, Lavie Bio intends Yalos® to be commercially ...

The collaboration has the power to foster breakthroughs in small molecule innovation for life science-based productsREHOVOT, Israel, Oct. 31, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced a collaboration with Google Cloud to develop a cutting-edge foundation model for generative small molecule de novo design, propelling Evogene's ChemPass AI tech-engine to ne ...

This shipment of castor seeds, developed by Casterra and produced in Kenya, is the first to complete the entire cultivation and processing cycle in Kenya. The company is now focused on preparing upcoming shipments, which will be delivered to its customers over the coming months. Currently, approximately 700 additional hectares are sown with Casterra's premium varieties in Kenya, with harvest expected later this year and into early 2025. The castor seeds in this shipment were cultivated by experienced local ...

Following a successful first year, Israel Innovation Authority (IIA) approved financing second year of collaboration HAZEVA and REHOVOT, Israel, Oct. 8, 2024 /PRNewswire/ -- Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable aquaculture and biotech and Evogene Ltd. ("Evogene") (NASDAQ: EVGN)(TASE: EVGN), a leading computational biology company aiming to revolutionize lifescience-based product discovery and development, together with Ben-Gurion University (BGU), a re ...

As filed with the U.S. Securities and Exchange Commission on September 19, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 EVOGENE LTD. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Israel 2870 N/A (I.R.S. Employer Identification No.) 13 Gad Feinstein Street, Park Re ...

[Consolidated Interim Statements of Financial Position](index=2&type=section&id=Consolidated%20Interim%20Statements%20of%20Financial%20Position) [Financial Position Overview](index=2&type=section&id=Financial%20Position%20Overview) Total assets decreased to **$40,968 thousand** by June 30, 2024, from **$51,101 thousand**, mainly due to lower cash and property Consolidated Interim Statements of Financial Position (U.S. dollars in thousands) | Item | June 30, 2024 (Unaudited) | December 31, 2023 | | :---------------------------- | :------------------------ | :---------------- | | **CURRENT ASSETS:** | | | | Cash and cash equivalents | $ 9,484 | $ 20,772 | | Short-term bank deposits | 11,424 | 10,291 | | Trade receivables | 376 | 357 | | Other receivables and prepaid | 3,696 | 2,973 | | Inventories | 794 | 76 | | **Total Current Assets** | **25,774** | **34,469** | | **LONG-TERM ASSETS:** | | | | Long-term deposits and other | 30 | 28 | | Investment accounted for | 100 | - | | Right-of-use-assets | 729 | 980 | | Property, plant and equipment | 1,650 | 2,455 | | Intangible assets, net | 12,685 | 13,169 | | **Total Long-Term Assets** | **15,194** | **16,632** | | **TOTAL ASSETS** | **$ 40,968** | **$ 51,101** | | **CURRENT LIABILITIES:** | | |\ | Trade payables | $ 957 | $ 1,785 | | Employees and payroll accruals| 2,333 | 2,537 | | Lease liability | 558 | 853 |\ | Liabilities in respect of | 681 | 388 | | Deferred revenues and other | 548 | 362 | | Convertible SAFE | 10,392 | - | | Other payables | 816 | 1,019 | | **Total Current Liabilities** | **16,285** | **6,944** | | **LONG-TERM LIABILITIES:** | | |\ | Lease liability | 252 | 285 | | Liabilities in respect of | 4,247 | 4,426 | | Deferred revenues and other | 244 | 393 | | Convertible SAFE | - | 10,368 | | **Total Long-Term Liabilities**| **4,743** | **15,472** | | **SHAREHOLDERS' EQUITY:** | | |\ | Ordinary shares | 287 | 286 | | Share premium and other | 269,648 | 269,353 | | Accumulated deficit | (266,868) | (257,586) | | Equity attributable to equity | 3,067 | 12,053 | | Non-controlling interests | 16,873 | 16,632 | | **Total Equity** | **19,940** | **28,685** | | **TOTAL LIABILITIES AND EQUITY**| **$ 40,968** | **$ 51,101** | [Consolidated Interim Statements of Profit or Loss](index=3&type=section&id=Consolidated%20Interim%20Statements%20of%20Profit%20or%20Loss) [Profit or Loss Overview](index=3&type=section&id=Profit%20or%20Loss%20Overview) Revenues increased to **$5,104 thousand** for six months ended June 30, 2024, narrowing operating loss to **$(10,188) thousand** Consolidated Interim Statements of Profit or Loss (U.S. dollars in thousands) | Item | Six months June 30, 2024 (Unaudited) | Six months June 30, 2023 (Unaudited) | | :---------------------------------------------------------------- | :----------------------------------- | :----------------------------------- | | Revenues | $ 5,104 | $ 1,295 | | Cost of revenues | 847 | 783 | | **Gross profit** | **4,257** | **512** | | Operating expenses: | | | | Research and development, net | 8,817 | 10,169 | | Sales and marketing | 1,920 | 1,728 | | General and administrative | 3,184 | 3,312 | | Other expenses | 524 | - | | **Total operating expenses, net** | **14,445** | **15,209** | | **Operating loss** | **(10,188)** | **(14,697)** | | Financing income | 667 | 699 | | Financing expenses | (288) | (785) | | **Financing income (expenses), net** | **379** | **(86)** | | Share of loss of an associate | (20) | - | | **Loss before taxes on income** | **(9,829)** | **(14,783)** | | Taxes on income (tax benefit) | 1 | (24) | | **Loss** | **$ (9,830)** | **$ (14,759)** | | Attributable to: | | | | Equity holders of the Company | $ (9,282) | $ (13,294) | | Non-controlling interests | (548) | (1,465) | | **Total Loss** | **$ (9,830)** | **$ (14,759)** | | Basic and diluted loss per share, attributable to equity holders | $ (1.82) | $ (3.18) | | Weighted average number of ordinary shares used in computing loss | 5,087,029 | 4,177,554 | [Consolidated Interim Statements of Changes in Equity](index=5&type=section&id=Consolidated%20Interim%20Statements%20of%20Changes%20in%20Equity) [Equity Changes Overview](index=5&type=section&id=Equity%20Changes%20Overview) Total equity decreased to **$19,940 thousand** by June 30, 2024, from **$28,685 thousand**, primarily due to a net loss Consolidated Interim Statements of Changes in Equity (U.S. dollars in thousands) - Six months ended June 30, 2024 | Item | Share capital | Share premium and other capital reserves | Accumulated deficit | Total (Equity holders) | Non-controlling interests | Total equity | | :---------------------------------------------------------------- | :------------ | :--------------------------------------- | :------------------ | :--------------------- | :------------------------ | :----------- | | Balance as of January 1, 2024 | $ 286 | $ 269,353 | $ (257,586) | $ 12,053 | $ 16,632 | $ 28,685 | | Loss | - | - | (9,282) | (9,282) | (548) | (9,830) | | Issuance of ordinary shares, net of issuance expenses | 1 | 85 | - | 86 | - | 86 | | Forfeiture of non-controlling interests regarding share-based comp| - | 22 | - | 22 | (22) | - | | Share-based compensation and RSUs | - | 188 | - | 188 | 811 | 999 | | Balance as of June 30, 2024 | $ 287 | $ 269,648 | $ (266,868) | $ 3,067 | $ 16,873 | $ 19,940 | Consolidated Interim Statements of Changes in Equity (U.S. dollars in thousands) - Six months ended June 30, 2023 | Item | Share capital | Share premium and other capital reserves | Accumulated deficit | Total (Equity holders) | Non-controlling interests | Total equity | | :---------------------------------------------------------------- | :------------ | :--------------------------------------- | :------------------ | :--------------------- | :------------------------ | :----------- | | Balance as of January 1, 2023 | $ 235 | $ 261,402 | $ (233,707) | $ 27,930 | $ 6,860 | $ 34,790 | | Loss | - | - | (13,294) | (13,294) | (1,465) | (14,759) | | Issuance of ordinary shares, net of issuance expenses | 2 | 334 | - | 336 | - | 336 | | Forfeiture of non-controlling interests regarding share-based comp| - | 69 | - | 69 | (69) | - | | Issuance of a subsidiary ordinary shares to the Company | - | (809) | - | (809) | 809 | - | | Issuance of a subsidiary preferred shares to non-controlling interests| - | (238) | - | (238) | 9,761 | 9,523 | | Share-based compensation and RSUs | - | 294 | - | 294 | 925 | 1,219 | | Balance as of June 30, 2023 | $ 237 | $ 261,052 | $ (247,001) | $ 14,288 | $ 16,821 | $ 31,109 | [Consolidated Interim Statements of Cash Flows](index=7&type=section&id=Consolidated%20Interim%20Statements%20of%20Cash%20Flows) [Cash Flow Overview](index=7&type=section&id=Cash%20Flow%20Overview) Net cash used in operating activities decreased to **$(9,565) thousand**, with financing activities shifting to a net cash use Consolidated Interim Statements of Cash Flows (U.S. dollars in thousands) | Cash Flow Activity | Six months June 30, 2024 (Unaudited) | Six months June 30, 2023 (Unaudited) | | :---------------------------------------------------------------- | :----------------------------------- | :----------------------------------- | | **Cash flows from operating activities:** | | | | Loss | $ (9,830) | $ (14,759) | | Adjustments to reconcile loss to net cash used in operating activities: | | | | Depreciation | 800 | 807 | | Amortization of intangible assets | 484 | 481 | | Share-based compensation | 999 | 1,219 | | Revaluation of convertible SAFE | 24 | 220 | | Net financing expenses (income) | (222) | 6 | | Loss (gain) from sale of property, plant and equipment | 524 | (26) | | Share of loss of an associate | 20 | - | | Taxes on income (tax benefit) | 1 | (24) | | Changes in asset and liability items: | | | | Decrease (increase) in trade receivables | (19) | 170 | | Decrease (increase) in other receivables | (725) | 84 | | Decrease (increase) in inventories | (718) | 317 | | Increase (decrease) in trade payables | (762) | 26 | | Increase (decrease) in employees and payroll accruals | (204) | 172 | | Decrease in other payables | (214) | (162) | | Decrease in deferred revenues and other advances | (84) | (73) | | Interest received | 402 | 283 | | Interest paid | (41) | (66) | | Taxes paid | - | (10) | | **Net cash used in operating activities** | **$ (9,565)** | **$ (11,335)** | | **Cash flows from investing activities:** | | | | Purchase of property, plant and equipment | (172) | (483) | | Proceeds from sale of marketable securities | - | 6,924 | | Purchase of marketable securities | - | (503) | | Proceeds from sale of property, plant and equipment | 10 | 26 | | Investment in short term bank deposits, net | (990) | (13,560) | | **Net cash used in investing activities** | **$ (1,152)** | **$ (7,596)** | | **Cash flows from financing activities:** | | | | Issuance of a subsidiary preferred shares to non-controlling interests | - | 9,523 | | Proceeds from issuance of ordinary shares, net of issuance expenses | 86 | 336 | | Repayment of lease liability | (462) | (413) | | Proceeds from government and other grants | - | 1,089 | | Repayment of government grants | (142) | (35) | | **Net cash provided by (used in) financing activities** | **(518)** | **10,500** | | Exchange rate differences - cash and cash equivalent balances | (53) | (316) | | **Decrease in cash and cash equivalents** | **(11,288)** | **(8,747)** | | Cash and cash equivalents, beginning of the period | 20,772 | 28,980 | | **Cash and cash equivalents, end of the period** | **$ 9,484** | **$ 20,233** | [Notes to Consolidated Interim Financial Statements](index=9&type=section&id=Notes%20to%20Consolidated%20Interim%20Financial%20Statements) [NOTE 1: - GENERAL](index=9&type=section&id=NOTE%201%3A%20-%20GENERAL) Evogene is an **AI-driven computational biology company** with operating losses, seeking to finance operations through capital raising - Evogene is a computational biology company utilizing **AI-driven tech-engines (MicroBoost AI, ChemPass AI, GeneRator AI)** to develop life-science products, focusing on microbes, small molecules, and genetic elements[14](index=14&type=chunk) - The company incurred **operating losses of $10,188 thousand and $14,697 thousand** for the six months ended June 30, 2024 and 2023, respectively, and plans to finance operations through capital raising and collaborations[16](index=16&type=chunk) - Evogene established Finally Foods Ltd., an AI-driven company specializing in molecular farming for sustainable alternative proteins, holding approximately **40% of its share capital**[15](index=15&type=chunk) - Casterra Ag Ltd. received orders totaling **$9,100 thousand and $2,200 thousand in June 2023**, and an additional **$440 thousand order in June 2024**, for the sale of castor varieties for biofuel production[23](index=23&type=chunk) - The company engaged in several equity financing activities: issued **320 ordinary shares for $3 thousand in January 2024** via ATM offering, sold **850,000 ordinary shares for $8,500 thousand in a July 2023** registered direct offering, and issued **10,000 ordinary shares for $85 thousand in May 2024** through a new ATM agreement[26](index=26&type=chunk)[27](index=27&type=chunk)[28](index=28&type=chunk) - Evogene's operations are segmented into **Agriculture** (Evogene, Lavie Bio, AgPlenus), **Human** (Biomica, Canonic), and **Industrial** (Casterra Ag)[28](index=28&type=chunk) [NOTE 2: - SIGNIFICANT ACCOUNTING POLICIES](index=12&type=section&id=NOTE%202%3A%20-%20SIGNIFICANT%20ACCOUNTING%20POLICIES) Interim financial statements follow IAS 34 and IFRS, with **IFRS 18** introducing new presentation rules effective **January 1, 2027** - Interim consolidated financial statements are prepared in accordance with International Accounting Standard 34, 'Interim Financial Reporting,' and International Financial Reporting Standards ('IFRS') as issued by the IASB[30](index=30&type=chunk)[31](index=31&type=chunk) - IFRS 18, 'Presentation and disclosure in Financial Statements,' was issued in April 2024, replacing IAS 1, and introduces new requirements for presentation within the statement of profit or loss and disclosure of management-defined performance measures, effective January 1, 2027[33](index=33&type=chunk) [NOTE 3: - REVENUE FROM CONTRACTS WITH CUSTOMERS](index=13&type=section&id=NOTE%203%3A%20-%20REVENUE%20FROM%20CONTRACTS%20WITH%20CUSTOMERS) Total revenues for six months ended June 30, 2024, increased to **$5,104 thousand**, mostly recognized at a point in time Disaggregation of Revenue (U.S. dollars in thousands) | Timing of Revenue Recognition | Six months June 30, 2024 (Unaudited) | Six months June 30, 2023 (Unaudited) | | :---------------------------- | :----------------------------------- | :----------------------------------- | | Revenue recognized at a point in time | $ 3,849 | $ 496 | | Revenue recognized over time | 1,255 | 799 | | **Total Revenues** | **$ 5,104** | **$ 1,295** | [NOTE 4: - OTHER RECEIVABLES AND PREPAID EXPENSES](index=13&type=section&id=NOTE%204%3A%20-%20OTHER%20RECEIVABLES%20AND%20PREPAID%20EXPENSES) Other receivables and prepaid expenses increased to **$3,696 thousand** by June 30, 2024, due to higher suppliers' advances Other Receivables and Prepaid Expenses (U.S. dollars in thousands) | Item | June 30, 2024 | December 31, 2023 | | :------------------------ | :------------ | :---------------- | | Government authorities | $ 236 | $ 226 | | Grant receivables | - | 88 | | Prepaid expenses | 851 | 909 | | Suppliers advances (*) | 2,294 | 1,617 | | Other | 315 | 133 | | **Total** | **$ 3,696** | **$ 2,973** | - Suppliers' advances, primarily for castor seed growing services for Casterra Ag Ltd., increased from **$1,617 thousand at December 31, 2023**, to **$2,294 thousand at June 30, 2024** The estimation of potentially non-recoverable advances considers factors like geographic location, age of balance, supplier financial condition, and past experience[36](index=36&type=chunk) [NOTE 5: - LIABILITIES IN RESPECT OF GOVERNMENT GRANTS](index=13&type=section&id=NOTE%205%3A%20-%20LIABILITIES%20IN%20RESPECT%20OF%20GOVERNMENT%20GRANTS) Government grant liabilities increased to **$4,928 thousand** by June 30, 2024, with significant accumulated grants and repayments Liabilities in Respect of Government Grants (U.S. dollars in thousands) | Item | June 30, 2024 (Unaudited) | December 31, 2023 (Audited) | | :--------------------------------- | :------------------------ | :-------------------------- | | Balance at January 1, | $ 4,814 | $ 4,744 | | Grants received or to be received | 74 | 66 | | Royalties paid | (142) | (73) | | Amounts recorded in profit or loss | 182 | 77 | | **Balance at June 30 / December 31** | **$ 4,928** | **$ 4,814** | - The Company received research and development grants from the Israel Innovation Authority ('IIA') and is obligated to pay royalties of 3%-4% of revenues derived from financed projects, up to 100% of grants received As of June 30, 2024, accumulated grants amounted to **$9,223 thousand**, with **$3,741 thousand repaid**[37](index=37&type=chunk) [NOTE 6: - FINANCIAL INSTRUMENTS](index=14&type=section&id=NOTE%206%3A%20-%20FINANCIAL%20INSTRUMENTS) Short-term financial instruments' fair values approximate carrying amounts; SAFE agreement uses **Level 3 fair value hierarchy** - The carrying amounts of cash and cash equivalents, short-term investments, other receivables, trade payables, and other payables approximate their fair values due to their short-term maturities[38](index=38&type=chunk) - The fair value of liabilities in respect of government grants and lease liabilities is measured using a discount rate that reflects the applicable market rate of interest at the date the grants are received or the IBR of interest at the contract date, respectively[38](index=38&type=chunk) - The fair value measurement of the SAFE agreement is based on the weighted average value of various scenarios regarding Lavie Bio Ltd.'s estimated enterprise value, using the income approach, and is considered to be **Level 3 fair value hierarchy**[39](index=39&type=chunk) [NOTE 7: - SHARE- BASED COMPENSATION](index=14&type=section&id=NOTE%207%3A%20-%20SHARE-%20BASED%20COMPENSATION) Total share-based compensation expense was **$999 thousand** for six months ended June 30, 2024, for equity holders and non-controlling interests Share-Based Compensation Expenses (U.S. dollars in thousands) | Item | Six months June 30, 2024 (Unaudited) | Six months June 30, 2023 (Unaudited) | | :--------------------------------------------------- | :----------------------------------- | :----------------------------------- | | Share-based compensation - Attributable to equity holders | $ 188 | $ 294 | | Share-based compensation - Attributable to non-controlling interests | 811 | 925 | | **Total** | **$ 999** | **$ 1,219** | Evogene Share Options Activity | Item | 2024 Number of options | 2024 Weighted average exercise prices ($) | 2023 Number of options | 2023 Weighted average exercise prices ($) | | :------------------------ | :--------------------- | :---------------------------------------- | :--------------------- | :---------------------------------------- | | Outstanding on January 1, | 397,452 | 28.8 | 403,602 | 41.7 | | Granted | 13,300 | 7.0 | 47,100 | 7.1 | | Exercised | - | - | - | - | | Forfeited/Expired | (2,938) | 121.1 | (36,211) | 42.4 | | Outstanding on June 30, | 407,814 | 26.5 | 414,491 | 35.7 | | Exercisable at June 30, | 314,648 | 30.7 | 275,770 | 46.8 | Evogene RSUs Activity | Item | 2024 Number of RSUs | 2024 Weighted average grant date fair value | 2023 Number of RSUs | 2023 Weighted average grant date fair value | | :------------------------ | :------------------ | :------------------------------------------ | :------------------ | :------------------------------------------ |\ | Outstanding on January 1, | 41,420 | 12.4 | 19,658 | 25.5 | | Granted | 1,300 | 9.7 | 33,260 | 7.5 | | Vested | (7,127) | 14.8 | (3,153) | 26.1 | | Forfeited/Expired | (112) | 7.5 | (1,200) | 30.4 | | Outstanding on June 30, | 35,481 | 11.8 | 48,565 | 13.0 | Subsidiaries' Share Options Activity | Item | 2024 Number of options | 2024 Weighted average exercise prices ($) | 2023 Number of options | 2023 Weighted average exercise prices ($) | | :------------------------ | :--------------------- | :---------------------------------------- | :--------------------- | :---------------------------------------- | | Outstanding on January 1, | 2,531,134 | 1.63 | 2,273,489 | 1.72 | | Granted | 138,500 | 1.46 | 546,839 | 1.87 | | Exercised | (5,000) | 0.19 | - | - | | Forfeited/Expired | (748,576) | 0.21 | (473,932) | 3.15 | | Outstanding on June 30, | 1,916,058 | 2.17 | 2,346,396 | 1.46 | | Exercisable at June 30, | 1,037,638 | 2.01 | 1,390,561 | 0.94 | Total Compensation Cost by Expense Category (U.S. dollars in thousands) | Expense Category | Six months June 30, 2024 (Unaudited) | Six months June 30, 2023 (Unaudited) | | :---------------------------- | :----------------------------------- | :----------------------------------- | | Cost of revenues | $ 15 | $ - | | Research and development, net | 232 | 469 | | Sales and marketing | 345 | 297 | | General and administrative | 407 | 453 | | **Total** | **$ 999** | **$ 1,219** | [NOTE 8: - OPERATING SEGMENTS](index=17&type=section&id=NOTE%208%3A%20-%20OPERATING%20SEGMENTS) Evogene operates in **Agriculture**, **Human**, and **Industrial** segments, with Agriculture generating the highest revenue - Evogene operates in three segments: **Agriculture** (seed traits, ag-chemical, ag-biological products), **Industry** (improved castor bean seeds), and **Human** (human microbiome-based therapeutics, cannabis activity)[51](index=51&type=chunk) Revenues and Operating Loss by Segments (U.S. dollars in thousands) - Six months ended June 30, 2024 | Segment | Revenues | Operating loss | | :------------ | :------- | :------------- | | Agriculture | $ 4,648 | $ (3,104) | | Industry | 196 | (1,225) | | Human | 77 | (4,000) | | Unallocated | 183 | (1,859) | | **Total** | **$ 5,104**| **$ (10,188)** | Revenues and Operating Loss by Segments (U.S. dollars in thousands) - Six months ended June 30, 2023 | Segment | Revenues | Operating loss | | :------------ | :------- | :------------- | | Agriculture | $ 819 | $ (5,751) | | Industry | 28 | (156) | | Human | 300 | (4,795) | | Unallocated | 148 | (3,995) | | **Total** | **$ 1,295**| **$ (14,697)** | Revenues from Major Customers (Share of Total Revenues) | Customer | Six months June 30, 2024 (Unaudited) | Six months June 30, 2023 (Unaudited) | | :--------- | :----------------------------------- | :----------------------------------- | | Customer A | 58% | 49% | | Customer B | - | 22% | | Customer C | - | 12% | | Customer D | 26% | - | - Major contracts include Lavie Bio Ltd.'s licensing agreement with Corteva for bio-fungicides, which generated an **initial payment of $5,000 thousand** (received in two installments, **$2,500 thousand in March 2024**), and AgPlenus Ltd.'s Licensing and Collaboration Agreement with Bayer AG for a new weed control solution, entitling AgPlenus to license payments, research funding, milestones, and royalties[57](index=57&type=chunk)[58](index=58&type=chunk) Geographical Revenue Distribution | Region | Six months June 30, 2024 (Unaudited) | Six months June 30, 2023 (Unaudited) | | :------------ | :----------------------------------- | :----------------------------------- | | United States | 64% | 62% | | Europe | 27% | - | | Israel | 6% | 36% | | Africa | 3% | 2% | | **Total** | **100%** | **100%** | [NOTE 9: - SUBSEQUENT EVENTS](index=20&type=section&id=NOTE%209%3A%20-%20SUBSEQUENT%20EVENTS) Evogene implemented a **1-for-10 reverse share split** on July 24, 2024, and raised **$5.5 million** in an August 2024 offering - On July 23, 2024, Evogene announced and implemented a **1-for-10 reverse share split** of its ordinary shares, effective July 24, 2024, with proportionate adjustments to outstanding options and RSUs[61](index=61&type=chunk) - On August 26, 2024, Evogene issued and sold **265,000 ordinary shares** and pre-funded warrants to purchase up to **1,427,308 ordinary shares** in a registered direct offering, along with unregistered Series A and Series B ordinary warrants, generating approximately **$5.5 million in gross proceeds**[62](index=62&type=chunk)

REHOVOT, Israel, Aug. 23, 2024 /PRNewswire/ -- Evogene Ltd. ("Evogene" or the "Company") (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development utilizing cutting-edge computational biology technologies across multiple market segments, announced today that it has entered into definitive agreements with a single health-care focused institutional investor for the purchase and sale of 1,692,308 ordinary shares (or ordinary ...

Financial Data and Key Metrics - Total revenues for the first six months of 2024 reached approximately $5.1 million, compared to $1.3 million in the first half of 2023, driven by Casterra's seed supply and Lavie Bio's licensing agreement [6][29] - Q2 2024 revenues were approximately $914,000, up from $654,000 in Q2 2023, primarily due to increased revenues from Lavie Bio [7][30] - Net loss for the first half of 2024 was approximately $9.8 million, a significant improvement from $14.8 million in the same period last year, driven by increased revenues and decreased operating expenses [7][34] - Projected cash usage for 2024, excluding Biomica and Lavie Bio, is approximately $8 million, a 36% decrease from $12.5 million in 2023 [7][29] Business Line Performance - **Casterra**: Received an additional purchase order of $440,000 for castor seeds, with total existing orders amounting to $8.4 million expected to be fulfilled by the end of 2024 [8][14] - **Biomica**: Preliminary Phase 1 trial results for BMC128 showed promising efficacy and safety in treating refractory cancers, with data presented at ASCO 2024 [9][16] - **Lavie Bio**: Expanded its bio-inoculant product Yalos to winter wheat, doubling its market potential, and identified over a dozen novel microbial candidates using its BDD technology platform [9][15] Market and Strategic Direction - The global castor oil market is projected to reach $1.68 billion by 2028, driven by increasing demand for sustainable and renewable resources in bio-based industries [20][22] - Casterra aims to establish itself as a leading provider of sustainable vegetable oil feedstock, particularly for the biofuel sector, leveraging its elite castor seed varieties and advanced cultivation techniques [18][21] - Evogene's AI-driven tech-engines (MicroBoost AI, ChemPass AI, GeneRator AI) are designed to optimize life science product development across various market segments, focusing on efficiency and cost-effectiveness [10][11] Management Commentary on Future Prospects - Management anticipates continued revenue growth in the second half of 2024, driven by Casterra's seed supply and Lavie Bio's product expansion [6][30] - The company is exploring the potential to expand into castor oil production, which could further enhance its market position and revenue streams [27][28] - Evogene's subsidiaries are advancing their pipelines, with significant milestones expected in Q4 2024, particularly in Lavie Bio's field trials and Biomica's clinical development [15][17] Q&A Session Summary Question: What is Casterra's current backlog for 2025, and will oil production be based in Africa or Brazil? - Casterra is working on its 2025 backlog, with details expected in the next analyst call. Oil production is under evaluation, with potential locations in both Africa and Brazil [35][36] Question: Can you provide an update on AgPlenus? - AgPlenus is focused on building a new pipeline, particularly in fungicides, and is collaborating with Bayer and Corteva. Updates are expected in the next quarter [37][38] Question: What is the trajectory of Casterra's castor seed launch in 2H 2024, and what is the current gross margin profile? - Casterra aims to fulfill $8.4 million in seed orders by the end of 2024, with a current production capacity of over 1,000 hectares. Gross margins are high, particularly in seed sales, with potential for further improvement in oil production [40][42] Question: When should we expect material revenue contribution from Yalos? - Yalos is expected to see material growth in sales by 2026, with early adoption in soybean and canola markets starting in 2025 [43][44] Question: What is Evogene's expected cash position by the end of 2024? - Assuming $8.4 million in castor seed revenues, Evogene's cash position is expected to be around $18-19 million by the end of 2024 [46][47]

Conference call and webcast: today, August 22, 2024, 9:00 am ET Financial and Business Highlights: H1 2024 revenues $5.1M, up from $1.3M in H1 2023; Q2 2024 revenues $914K, up from $654K in Q2 2023. Anticipated continued revenue growth in the second half of 2024 compared to the same period in the previous year, primarily driven by Casterra's initiation of supplying existing seed orders, which began in August 2024 and total over $8.0 million. H1 2024 loss $9.8M, down from $14.8M in H1 2023; Q2 2024 loss $6.0 ...

Core Points - Evogene Ltd. has regained compliance with Nasdaq Listing Rule 5550(a)(2) after its ordinary shares maintained a minimum bid price of $1.00 for 10 consecutive business days [1][2] - The compliance issue regarding the bid price deficiency is now considered closed by Nasdaq [2] Company Overview - Evogene Ltd. is a computational biology company that utilizes big data and artificial intelligence to enhance the development of life-science products, aiming to increase success rates while reducing time and costs [3] - The company has established three unique tech-engines: MicroBoost AI, ChemPass AI, and GeneRator AI, each focusing on different core components such as microbes, small molecules, and genetic elements [4] - Evogene operates through five subsidiaries, including Biomica Ltd., Lavie Bio Ltd., AgPlenus Ltd., and Casterra Ag Ltd., which are involved in developing microbiome-based therapeutics, ag-biologicals, next-generation ag chemicals, and superior castor seed varieties respectively [4]